Dr. Marc Elieson discusses concerns about COVID-19 and kids going back to school
Baylor Scott and White Health
Exposure to common cold-causing coronaviruses may contribute to pre-existing immunity to COVID-19, according to a new study involving a Rutgers research scientist.
A new method to assess the status of immune responses to specific antigens in detail by analysis using the B cell receptor (BCR) repertoire(*1) has been developed by a research group.
The start of the school year can be tough for many children. For some, the struggle might last just a few days. For others, however, a difficult transition back to school might be a sign of an undetected behavioral or developmental condition that requires medical attention.
Before they had access to livestock vaccines, many women in rural parts of Africa who manage livestock had to resort to traditional medicines when their animals got sick, or suffer loss of their animals.
Prior vaccination against tetanus and diphtheria, with or without pertussis (Tdap/Td); herpes zoster (HZ), better known as shingles; and pneumococcus are all associated with a reduced risk for developing Alzheimer’s disease, according to new research from UTHealth Houston.
Variety of health back to school pitches from the experts at Hackensack Meridian Children's Health
Vaccinations, blood tests, or IVs – it’s fair to say that no child likes a needle. So, when it comes to the jab, a light touch and a caring approach is incredibly welcomed – both by the child and the parent. Now, world-first research from the University of South Australia shows that while many children suffer distress, new ultrasound-guided techniques could provide much-needed reprieve.
Unexpected new insights into how COVID-19 infects cells may help explain why coronaviruses are so good at jumping from species to species and will help scientists better predict how COVID-19 will evolve.
Over 50 million K-12 students across the United States will return to classrooms this month, according to the National Center for Education Statistics. Michigan State University experts provide guidance on how to ensure students are physically and mentally prepared for the new school year.
Madagascar is one of the poorest countries in the world and access to health care is limited for many people. A new study from the University of Illinois Urbana-Champaign examines the effectiveness of a health intervention program that enlists community-based health workers to promote child vaccination uptake.
Medical experts offer tips on various back to school health concerns to prepare for a healthy successful school year.
The Rapid Assessment of Platform Technologies to Expedite Response project aims to prepare against future pandemics.
Deep-learning technology developed by a team of Johns Hopkins engineers and cancer researchers can accurately predict cancer-related protein fragments that may trigger an immune system response. If validated in clinical trials, the technology could help scientists overcome a major hurdle to developing personalized immunotherapies and vaccines.
Cedars-Sinai and BlackDoctor.org will host a virtual community conversation to help kick-off the back-to-school season.
University of Adelaide researchers have started work on developing a new vaccine that could help ward off painful ear infections in children. The potential vaccine is in the initial stages of development in the lab and will target one of the main types of bacteria that cause middle ear infections, a common illness among infants and young children.
A collaborative research effort led by the University of Michigan and the Icahn School of Medicine at Mount Sinai has resulted in a nasal vaccine adjuvant that stops COVID infection in both young and old mice.
At the beginning of the mass vaccination against COVID-19 infection, the government had to determine eligibility for priority vaccination.
Which types of personalities were more hesitant about COVID-19 vaccination during the pandemic’s peak? Extroverts — according to a new study on more than 40,000 Canadians.
Even vulnerable people, who are at risk of severe Covid-19, achieved good antibody levels after three doses of mRNA vaccine.
The coronavirus pandemic is no longer a national emergency, but the virus that causes COVID-19 isn’t gone—and neither is the risk of getting the disease. For parents, navigating when to get their child vaccinated and knowing how to best protect their child from COVID-19 can be complicated. We spoke to Michael Smit, MD, MSPH, Hospital Epidemiologist and Medical Director of Infection Prevention and Control at Children’s Hospital Los Angeles, to get an update on the latest COVID-19 vaccine information and precautions.
Today, the National Institutes of Health launched and is opening enrollment for phase 2 clinical trials that will evaluate at least four potential treatments for long COVID, with additional clinical trials to test at least seven more treatments expected in the coming months. Treatments will include drugs, biologics, medical devices and other therapies.
In a new study, scientists at La Jolla Institute for Immunology (LJI) compared the immune response of individuals who received older versus newer versions of the whooping cough vaccine. The unexpected findings may help explain the recent rise in whooping cough cases and point to potential targets for the next generation of vaccines.
Cancer patients saw a significant fall in Covid-related hospitalisations and mortality following the rollout of vaccines in the first panoramic study of its kind.
Immune system researchers have designed a computational tool to boost pandemic preparedness. Scientists can use this new algorithm to compare data from vastly different experiments and better predict how individuals may respond to disease.
A new paper in Biology Methods & Protocols, published by Oxford University Press, shows it may be possible to design vaccines that will induce a stronger immune response to infecting pathogens, such as the virus causing COVID-19.
An analysis of real-world data from more than 1.2 million patients from health systems in four geographically dispersed states -- Indiana, Oregon, Texas and Utah -- conducted by the U.S. Centers for Disease Control and Prevention’s VISION Network, has determined both the number of adults needed to be vaccinated to prevent one COVID-19 associated hospitalization and the number needed to be vaccinated to prevent one COVID-19 associated emergency department (ED) visit.
When people who publicly reject COVID-19 vaccines later die from the disease, observers have complex reactions to their fates, a new study suggests. While very few rejoice in the deaths of anti-vaxxers, some people believe those who are dogmatic against vaccines are deserving of worse outcomes – and that reaction is related to the political party affiliation and vaccination status of the person evaluating the anti-vaxxer.
The Icahn School of Medicine at Mount Sinai in New York, NY is pleased to announce that CastleVax, Inc. has completed enrollment and a preliminary analysis of a phase 1 trial of its licensed Newcastle disease virus (NDV)-based COVID-19 booster vaccine.
A vaccine candidate that can protect children from Meningococcal group B (MenB), which can lead to meningitis, has progressed to clinical development, according to an announcement by researchers from the University of Surrey and the University of Oxford.
CEPI to provide up to $4.98 USD million to Houston Methodist Research Institute-led consortium to use artificial intelligence for design of vaccines to fight diseases with pandemic potential. The project will support a consortium, led by HMRI, to design potential antigenic targets for up to 10 priority virus families with epidemic or pandemic potential. Laboratory-based tests will then be used to verify antigen designs for possible further development.
BU research highlights how healthcare inequities between urban and rural areas, and vaccine skepticism, played a role in deaths related to COVID.
Giving patients with operable pancreatic cancers a three-pronged combination immunotherapy treatment consisting of the pancreatic cancer vaccine GVAX, the immune checkpoint therapy nivolumab and urelemab, an anti-CD137 agonist antibody treatment, is safe, it increases the amount of cancer-killing immune system T cells in the tumors and it appears effective when given two weeks prior to cancer-removal surgery, according to new research directed by Johns Hopkins investigators.
Human papillomavirus (HPV) is a ubiquitous virus, and most people are infected at some point in their lives. HPV can infect epithelial cells of the skin and mucosa at various sites.
A new study conducted by researchers at Bar-Ilan University in Israel has shed light on the long-term impact of COVID-19 on the quality of life among different ethnic groups in the country. The study, part of a larger cohort project, highlights a significant discrepancy between Arabs and Druze, and Jews, with the two former groups experiencing a more pronounced decline in quality of life one year after infection.
A research group from Japan has developed a method to produce highly active mRNA vaccines at high purity using a unique cap to easily separate the desired capped mRNA.
A UCLA-led team has received $925,000 as part of a new grant from the Centers for Disease Control and Prevention (CDC) to conduct four surveillance projects tracking outbreaks of mpox--formerly known as monkeypox—across the U.S.
A roundup of the latest medical discoveries and faculty news at Cedars-Sinai for June 2023.
COVID-19 vaccination helped reduce disparities in disease incidence between low- and high-income communities, according to a new analysis led by Cedars-Sinai investigators.
Johns Hopkins Medicine scientists say they have developed a nanoparticle — an extremely tiny biodegradable container — that has the potential to improve the delivery of messenger ribonucleic acid (mRNA)-based vaccines for infectious diseases such as COVID-19, and vaccines for treating non-infectious diseases including cancer.
A new study by researchers in the UNC School of Medicine, including Meghan Rebuli, PhD, Ilona Jaspers, PhD, and Kevin T. Cao, lead author, has found that SARS-CoV-2 mRNA vaccination induces an immune response in the mucosal lining of the nasal cavity, offering new insights into potential vaccine strategies in the future.
A 2022 outbreak of mpox (formerly monkeypox) sickened more than 30,000 people and caused 38 deaths in the United States. It highlighted the lack of an approved vaccine for those under 18 years old.
A team of researchers from the Chinese Academy of Sciences, the Chinese Academy of Agricultural Sciences, and Beijing Institute of Pharmacology and Toxicology have made significant progress in developing multi-valent mRNA vaccines against monkeypox virus (MPV), the agent that can cause smallpox-like disease in humans.
A new study from researchers at the University of Wisconsin–Madison offers a first-of-its-kind visual of a non-mammal species' adaptive immune system in action. The advance holds potential implications for a range of scientific aims, from improving wildlife vaccines to better understanding fundamental disease processes and possibly the evolution of adaptive immunity itself.
Researchers from Children’s Hospital of Philadelphia (CHOP) have engineered stable, universal MHC-I molecules that can be produced rapidly at scale, allowing researchers not only to develop vaccines and immunotherapies more quickly but also to identify molecules that can work broadly across the population. The findings were published today in the Proceedings of the National Academy of Sciences.